On this page
What it is
What Is Orforglipron?Orforglipron is a GLP-1 receptor agonist approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Sold under the brand name Foundayo by Eli Lilly, it received FDA approval on April 1, 2026.
What makes orforglipron fundamentally different from every previous GLP-1 drug is its chemical nature: it is a small molecule , not a peptide. All prior GLP-1 drugs, semaglutide, tirzepatide, liraglutide, are large peptide molecules that must be injected because they would be destroyed in the digestive tract if swallowed. Orforglipron's small-molecule structure survives oral administration intact.
While orforglipron acts on the same GLP-1 receptor as semaglutide and tirzepatide , its small-molecule design means it was engineered computationally rather than derived from a naturally occurring hormone, a distinct category of drug development.
What people research it for
Is orforglipron a peptide?
Human studiesNo. Unlike semaglutide and tirzepatide, orforglipron is a small molecule, not a peptide. This is what allows it to be taken as an oral pill without the fasting requirements of oral semaglutide (Rybelsus).
How much weight can I lose on orforglipron?
Human studiesPhase 3 data from the ATTAIN-1 trial showed approximately 15% mean body weight loss at 72 weeks at the highest doses. ATTAIN-MAINTAIN also found that oral orforglipron preserved 74.7% of prior tirzepatide weight reduction and 79.3% of prior semaglutide weight reduction over 52 weeks after switching from injectable GLP-1 therapy.
Do I need to fast before taking orforglipron?
Human studiesNo. This is a major advantage over oral semaglutide (Rybelsus), which requires 30 minutes of fasting before and after taking it. Orforglipron can be taken with or without food at any time of day.
How it works
How Does Orforglipron Work?Orforglipron is a non-peptide, oral GLP-1 receptor agonist. It binds to and activates the GLP-1 receptor, the same target as injectable GLP-1 drugs, but through a structurally distinct mechanism that enables oral bioavailability.
1. Appetite Suppression (Central Nervous System)
Like injectable GLP-1 drugs, orforglipron activates GLP-1 receptors in the hypothalamus and brainstem, brain regions that regulate hunger and satiety. This reduces appetite and “food noise,” leading to lower caloric intake without requiring willpower.
2. Delayed Gastric Emptying
Orforglipron slows the rate at which food leaves the stomach, extending post-meal fullness and naturally reducing portion sizes and snacking. This is the same mechanism seen with injectable GLP-1 agonists.
3. Glucose-Dependent Insulin Secretion
When blood glucose rises after eating, orforglipron stimulates insulin release from pancreatic beta cells. Crucially, this effect is glucose-dependent, it only activates when blood sugar is elevated, which minimizes the risk of hypoglycemia.
4. Small-Molecule Advantage: Oral Bioavailability
Unlike peptide GLP-1 drugs, orforglipron's small-molecule structure resists degradation in the GI tract and is absorbed efficiently without fasting requirements. This is the key chemical engineering breakthrough, achieving the same receptor activation as injected peptides via a simple daily pill.
The net effect: You eat less because you're genuinely less hungry. Blood sugar stabilizes. Over time, this sustained caloric deficit produces significant, sustained weight loss, comparable to what injectable GLP-1 drugs achieve.
What the research actually shows
Orforglipron has been studied in the ACHIEVE and ATTAIN trial programs. The data supporting FDA approval comes primarily from the Phase 3 ATTAIN-1 trial, with earlier efficacy data from the Phase 2 ACHIEVE-1 trial.
Phase
Phase 2
Guide status and key facts
Key Facts at a Glance
- Drug class
- GLP-1 receptor agonist (small molecule)
- Administration
- Once-daily oral tablet, no injections
- FDA approval
- April 1, 2026 (weight loss)
- Average loss
- ~15% body weight (72 wks)
- Manufacturer
- Eli Lilly
- Food restrictions
- None, take with or without food
Clinical Trial Evidence
Orforglipron has been studied in the ACHIEVE and ATTAIN trial programs. The data supporting FDA approval comes primarily from the Phase 3 ATTAIN-1 trial, with earlier efficacy data from the Phase 2 ACHIEVE-1 trial.
ACHIEVE-1, Phase 2 Dose-Finding Trial
Phase
Phase 2
Duration
26 weeks
Published
NEJM, 2023
Adults with obesity or overweight with weight-related comorbidities. Multiple daily doses tested vs. placebo. The 36 mg dose arm showed the primary result.
| Outcome | Orforglipron 36 mg | Placebo |
|---|---|---|
| Mean body weight loss | 7.2% | ~1.4% |
| Timepoint | 26 weeks | 26 weeks |
Note: 26 weeks is mid-escalation, the full weight loss effect accrues over 72+ weeks.
ATTAIN-1, Pivotal Phase 3 Trial
Phase
Phase 3
Duration
72 weeks
Population
Adults with obesity
The pivotal trial that supported FDA approval. Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, randomized to orforglipron (highest dose) or placebo with lifestyle counseling.
| Outcome | Orforglipron | Placebo |
|---|---|---|
| Mean body weight loss | ~15% | ~2% |
| Timepoint | 72 weeks | 72 weeks |
For a 250-pound person, ~15% = approximately 37 pounds lost over 72 weeks.
What the trials tell us:
- ~15% average weight loss at 72 weeks, comparable to injectable semaglutide
- Efficacy appears to plateau by months 12 to 16, similar to other GLP-1 drugs
- No food or water fasting required, unlike oral semaglutide (Rybelsus)
- Side effect profile mirrors injectable GLP-1 drugs but may be milder due to daily dosing. See our side effects management guide
- Individual results vary. Some achieve greater loss, some less
Orforglipron vs. Other GLP-1s
How does orforglipron stack up against established GLP-1 options? Here's a direct comparison across the key dimensions patients care about most.
| Drug | Form | Frequency | Avg. Loss | Fasting req? |
|---|---|---|---|---|
| Orforglipron (Foundayo) | Oral pill | Daily | ~15% | No |
| Semaglutide (Wegovy) | Injection | Weekly | ~15% | N/A (injected) |
| Semaglutide oral (Rybelsus) | Oral pill | Daily | ~10–13% | Yes, 30 min |
| Tirzepatide (Zepbound) | Injection | Weekly | ~22.5% | N/A (injected) |
Orforglipron vs. Injectable Semaglutide (Wegovy)
Head-to-head: comparable weight loss (~15%), fundamentally different delivery. Orforglipron wins on convenience; injectable semaglutide wins on longer real-world evidence and established insurance coverage pathways. For injection-averse patients, orforglipron is the obvious first choice at equivalent efficacy.
Orforglipron vs. Tirzepatide (Zepbound)
Tirzepatide's dual GLP-1/GIP mechanism delivers substantially greater weight loss (~22.5% vs ~15%). For patients who can tolerate injections and want maximum efficacy, tirzepatide remains the superior option. Orforglipron's advantage is delivery format, not magnitude of effect. See our full tirzepatide vs. semaglutide comparison for more detail.
Orforglipron vs. Oral Semaglutide (Rybelsus)
Both are daily oral GLP-1 options, but orforglipron has a clear practical edge: no fasting requirement. Rybelsus requires 30 minutes of fasting before and after each dose, a real-world barrier to adherence. Orforglipron's weight loss data (~15%) also appears stronger than oral semaglutide at standard doses (~10–13%).
Handling & storage
Storage at a glance
FDA label- Light
- Light-sensitive. Keep in the original bottle and carton, and replace the cap after each use.
- Room temperature
- Store at 20 to 25°C. Excursions are permitted from 15 to 30°C.
Basis: FDA label. Sources: DailyMed FOUNDAYO label, FDA FOUNDAYO approval letter
FOUNDAYO is a light-sensitive non-peptide tablet. Store it at 20 to 25°C, with permitted excursions from 15 to 30°C, in the original bottle and carton. Replace the cap after each use.
No refrigeration or reconstitution instructions belong in this guide. Follow the tablet label rather than peptide-vial handling rules.
Safety & cautions
Orforglipron's side effects are consistent with the GLP-1 drug class, predominantly gastrointestinal. However, because it is dosed daily rather than in a weekly injection (which creates a peak concentration), some researchers hypothesize that the GI side effects may be milder in practice. This has not yet been directly confirmed in head-to-head comparisons.
As a GLP-1 receptor agonist, orforglipron carries a black box warning for thyroid C-cell tumors. GLP-1 agonists caused thyroid tumors in rodent studies; relevance to humans is unknown. Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
2026 Maintenance Evidence: After Injectable GLP-1 Weight Loss
ATTAIN-MAINTAIN, published in Nature Medicine in May 2026 by Louis J. Aronne and colleagues, tested whether people who had already lost substantial weight on injectable GLP-1 therapy could preserve more of that loss by switching to oral orforglipron rather than placebo. This is maintenance-phase evidence, not a starter-treatment trial.
ATTAIN-MAINTAIN, Phase 3b Maintenance Trial
Participants
376
Duration
52 weeks
Prior trial
SURMOUNT-5
| Prior injectable | Orforglipron | Placebo |
|---|---|---|
| Tirzepatide cohort, n=205 | 74.7% maintained | 49.2% maintained |
| Semaglutide cohort, n=171 | 79.3% maintained | 37.6% maintained |
Participants switching from tirzepatide to orforglipron gained an average of 5 kg over the maintenance year, while those switching from semaglutide gained about 1 kg. The study also reported preservation of cardiometabolic benefits, including waist circumference, blood pressure, blood sugar, triglycerides, and cholesterol measures.
Dosing schedule
Orforglipron uses a gradual dose escalation, taken once daily. Unlike injectable GLP-1 drugs (weekly peaks) or oral semaglutide (fasting required), it is simply swallowed once a day with or without food.
Orforglipron (Foundayo) Escalation Schedule
| Duration | Daily Dose | Purpose |
|---|---|---|
| Weeks 1–4 | 3 mg | Initiation, body adjustment |
| Weeks 5–8 | 6 mg | First escalation |
| Weeks 9–12 | 12 mg | Second escalation |
| Weeks 13–16 | 24 mg | Third escalation |
| Weeks 17–20 | 36 mg | Fourth escalation |
| Week 21+ | 45 mg | Maintenance dose |
Dosing notes:
- Escalate every 4 weeks, do not rush ahead to minimize GI side effects
- If side effects are intolerable at a given dose, your physician may slow escalation
- Take at a consistent time each day to build a habit
- Do not double up on missed doses
Side Effects
Orforglipron's side effects are consistent with the GLP-1 drug class, predominantly gastrointestinal. However, because it is dosed daily rather than in a weekly injection (which creates a peak concentration), some researchers hypothesize that the GI side effects may be milder in practice. This has not yet been directly confirmed in head-to-head comparisons.
Common (>10% of patients)
- Nausea, Most common; typically worst during escalation
- Diarrhea, Usually mild to moderate
- Vomiting, More frequent at higher doses
- Constipation, Can alternate with diarrhea
- Abdominal discomfort, Usually mild and transient
Less Common (1–10%)
- Headache
- Fatigue
- Dizziness
- Bloating / gas
- Decreased appetite (desired effect, but can be pronounced)
- Hair thinning (from rapid weight loss, not the drug itself)
Serious Side Effects (Rare but Important)
- Pancreatitis, Seek immediate care for severe, persistent abdominal pain
- Gallbladder problems, Rapid weight loss increases gallstone risk
- Kidney injury, Typically from dehydration due to severe vomiting or diarrhea
- Hypoglycemia, Rare with orforglipron alone; possible if combined with insulin or sulfonylureas
FDA Black Box Warning
As a GLP-1 receptor agonist, orforglipron carries a black box warning for thyroid C-cell tumors. GLP-1 agonists caused thyroid tumors in rodent studies; relevance to humans is unknown. Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Managing Side Effects
- Follow the escalation schedule, do not skip dose levels
- Eat smaller, more frequent meals; avoid high-fat or greasy foods
- Stay well hydrated; eat slowly and mindfully
- If nausea is severe, ask your doctor about slowing the escalation
Cost and Access
Foundayo (orforglipron) received FDA approval on April 1, 2026. As of early April 2026, Eli Lilly has not yet announced a list price. Based on competitive dynamics, pricing is expected to be in a similar range to other branded GLP-1 weight loss medications.
Foundayo (orforglipron)
- List price
- Not yet announced
- Expected range
- Competitive with Wegovy/Zepbound
- Insurance coverage
- TBD, rollout in progress
Eli Lilly offers patient support programs for its other obesity drugs; similar programs are expected for Foundayo. Check the Foundayo website for the latest savings card information once available.
Comparable branded alternatives
- Wegovy (semaglutide)
- ~$1,349/mo list
- Zepbound (tirzepatide)
- ~$1,059/mo list
Prices with insurance vary significantly. Many commercial plans now cover GLP-1 obesity medications for qualifying patients.
Watch Orforglipron prices
We'll email you when prices drop, a discount code changes, or new lab results come in for Orforglipron. No spam — only real changes.
Frequently asked questions
Is orforglipron a peptide?
No. Unlike semaglutide and tirzepatide, orforglipron is a small molecule, not a peptide. This is what allows it to be taken as an oral pill without the fasting requirements of oral semaglutide (Rybelsus).
How much weight can I lose on orforglipron?
Phase 3 data from the ATTAIN-1 trial showed approximately 15% mean body weight loss at 72 weeks at the highest doses. ATTAIN-MAINTAIN also found that oral orforglipron preserved 74.7% of prior tirzepatide weight reduction and 79.3% of prior semaglutide weight reduction over 52 weeks after switching from injectable GLP-1 therapy.
Do I need to fast before taking orforglipron?
No. This is a major advantage over oral semaglutide (Rybelsus), which requires 30 minutes of fasting before and after taking it. Orforglipron can be taken with or without food at any time of day.
When was orforglipron FDA approved?
Orforglipron (Foundayo) received FDA approval on April 1, 2026, for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
How does orforglipron compare to Wegovy or Zepbound?
Orforglipron's ~15% weight loss is comparable to injectable semaglutide (Wegovy, ~15%) but below tirzepatide (Zepbound, ~22%). The key advantage is convenience: a daily pill with no injections and no fasting requirements.
What are the most common side effects of orforglipron?
The most common side effects are nausea, diarrhea, and vomiting, the same GI profile as injectable GLP-1 drugs. Because orforglipron is dosed daily rather than in a weekly bolus, some evidence suggests peak GI effects may be milder.
What is the starting dose of orforglipron?
Treatment begins at 3 mg daily and escalates every 4 weeks: 3 mg to 6 mg to 12 mg to 24 mg to 36 mg to 45 mg (maintenance). The escalation schedule is designed to minimize gastrointestinal side effects.
The Bottom Line
Orforglipron (Foundayo) is a genuine landmark in obesity pharmacology. For the first time, GLP-1 receptor agonist therapy is available as a simple daily pill - no injections, no fasting, no cold-chain logistics. The weight loss (~15% at 72 weeks) is clinically meaningful and comparable to injectable semaglutide.
It is not a maximum-efficacy option. Tirzepatide (Zepbound) still delivers substantially greater weight loss (~22.5%), and the early data from retatrutide trials suggests even higher potential. But for the large population of patients who have resisted GLP-1 therapy specifically because of the injection barrier, orforglipron is a compelling and scientifically validated alternative.
The biggest near-term unknowns are pricing and insurance coverage, both of which will determine how many patients can actually access it. The newest evidence also positions orforglipron as a possible maintenance tool after injectable GLP-1 weight loss, although it preserved most, not all, of prior weight reduction in ATTAIN-MAINTAIN.
Source details
- 1.Wharton S, et al. “Orforglipron, a Nonpeptide GLP-1 Receptor Agonist for Weight Management.” New England Journal of Medicine, 2023. ACHIEVE-1 Phase 2 trial.
- 2.Eli Lilly and Company. ATTAIN-1 Phase 3 trial results (orforglipron for obesity). Press release and FDA submission data, 2025–2026.
- 3.U.S. Food and Drug Administration. “FDA Approves Foundayo (orforglipron) for Chronic Weight Management.” FDA press release, April 2026.
- 4.Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021. STEP 1 trial (reference for semaglutide comparator data).
- 5.Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022. SURMOUNT-1 trial (reference for tirzepatide comparator data).
- 6.Aronne LJ, et al. “Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.” Nature Medicine, 2026.
- 7.Kaplan LM, et al. “Comparative Efficacy and Tolerability of Medications for Weight Loss: A Systematic Review.” Annals of Internal Medicine, 2022.
Medical disclaimer
Sources
Last reviewed May 19, 2026. This guide is educational and research-focused, not medical advice. Orforglipron products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.
GO DEEPER
This guide covers one compound. We wrote the book on all 45.
The Peptide Handbook takes everything we know from testing vendors for a living and turns it into five readable books: what each compound actually does, what the evidence really says, and the honest call when the answer is "skip this one." Plus the dosing tables, calendars, and trackers that make it usable.
From the community
Ask a questionNo Orforglipron discussions yet — ask the first question and our team will answer.